The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease

Who can take part

• Age ≥ 18 years at time of informed consent signature
• Informed Consent Form (ICF) is signed by the subject
• Subject can comply with protocol requirements, including follow-up
• Patient has symptomatic claudication, rest pain, or minor tissue loss (Rutherford Category 2-5)
• Patient has de novo or restenotic lesion(s) found in the common and/or external iliac artery(ies)
• Patient has: Unilateral or bilateral single or multiple lesions (>50% stenosis or chronic total occlusion) each between 4 and 11 cm in length
• Patient has a target vessel diameter visually estimated to be approximately between 5 mm and 13 mm
• Patient has a sufficient (<50% stenotic) common femoral artery and at least one sufficient (<50% stenotic) femoral artery (deep or superficial)
• Patient has at least one sufficient (<50% stenotic) infrapopliteal run-off vessel

Who cannot take part

• Patient has a known intolerance to antithrombotic medications that prevent compliance with study or control device Instructions for Use
• Patient has previous stenting in the iliac arteries
• Patient has previous surgical bypass in the target limb
• Patient is currently participating in another investigative clinical study unless received written approval by the sponsor
• Patient has a lesion requiring drug-coated balloon angioplasty, atherectomy, lithotripsy, or any ablative device to facilitate stent delivery
• Patient has isolated common iliac artery stenosis that can be treated with a single device (i.e., common iliac artery stenosis that does not require kissing stents or extend into the external iliac artery)
• Patient has outflow disease that requires concomitant interventions (i.e. common femoral endarterectomy or femoral / tibial revascularization)
• Patient has a known allergy to stent or stent graft components (including nitinol, stainless steel, or heparin)
• Patient has evidence of a systemic infection
• Patient has severe chronic renal insufficiency (serum creatinine level > 2.5mg/dL) and not undergoing hemodialysis
• Life expectancy <1 year
• Patient is pregnant at time of informed consent
• Patient has had vascular catheterization of the lower extremities within 30 days of randomization (excluding diagnostic angiograms for the study procedure)
• Patient has an abdominal aortic artery lesion or aneurysm
• Patient has a lesion that requires stent placement within 2 cm of the inguinal ligament